Replies to post #766927 on NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Doc, Thanks for that. Amazing.

Adding from AI.

A reveal.... the significance of IFR Program?

IFR Program:
More commonly for:
o Licensed medicines used "off-label" (outside approved indications)
o Licensed medicines awaiting NHS routine commissioning decisions
o Medicines with regulatory approval but not yet routine NHS funding

The IFR pathway often handles products that have some form of regulatory approval but lack routine commissioning. DCVax-L/Murcidencel, if now under IFR, likely has some form of regulatory standing that makes "unlicensed" no longer the technically correct description.
The more appropriate terms in the IFR context would be "not routinely commissioned" or "requiring exceptional approval" rather than "unlicensed."

Understanding from Specials to IFR

Specials vs. IFR: A Major Evolution for DCVax-L
Key Differences:
1. Regulatory Framework:
o Specials: MHRA pathway for "unlicensed" medicines
o IFR: NHS framework for recognized treatments requiring exceptional approval

2. Funding Responsibility:
o Specials: Patient out-of-pocket payment
o IFR: NHS covers treatment costs

3. Clinical Application:
o Specials: Glioblastoma only
o IFR: All tumor-based cancers

Why This Is Major:
This transition represents a significant advancement on three critical fronts simultaneously:
1. Regulatory Validation: Moving from "unlicensed" status to recognized treatment within NHS frameworks
2. Financial Access: Shifting cost burden from patients to the healthcare system
3. Therapeutic Scope: Expanding from a single rare cancer to potentially all solid tumors

Together, these changes transform DCVax-L from a niche, patient-funded experimental treatment to a recognized cancer therapy with NHS financial backing and broadly expanded clinical potential. This fundamentally changes both the accessibility and legitimacy of the treatment within the UK healthcare ecosystem.

Summary of why it is a big deal
DCVax status change from Specials Program to the now Individual Funding Request (IFR).

1. Money
The Specials Program falls under the MHRA and enables access to unlicensed medicines.
The IFR is a NHS funding mechanism.
In other words, Specials means self-funded (patient pays out-of-pocket), and now under IFR, the NHS covers the treatment costs.

2. Indication for Cancer Therapy
The Specials Program for DCVax-L was for GBM only.
Under IFR within the NHS commissioning framework, the indication for Murcidencel is "Cancer"

3. Patient accessibility
Specials means the physician take responsibility.
IFR provides a structured pathway for patient access, enables more consistent decision-making.

4. Data and RWE
IFR facilitates better data collection on treatment outcomes.

[beartrap12]

Doc, I agree. I always thought the addition 700,000 pages to the MAA was something "extra", which I may have expressed here on iHub as Flaskworks inclusion, tumor agnostic designation, or other gliomas. And I still believe it. Well, we'll know soon!